LU92854I2 - Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil - Google Patents
Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil Download PDFInfo
- Publication number
- LU92854I2 LU92854I2 LU92854C LU92854C LU92854I2 LU 92854 I2 LU92854 I2 LU 92854I2 LU 92854 C LU92854 C LU 92854C LU 92854 C LU92854 C LU 92854C LU 92854 I2 LU92854 I2 LU 92854I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- rilpivirine
- tenofovir
- protected
- pharmaceutically acceptable
- combination
- Prior art date
Links
- 229960002814 rilpivirine Drugs 0.000 title 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 2
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical class Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49977103P | 2003-09-03 | 2003-09-03 | |
| EP03103275 | 2003-09-03 | ||
| EP03103319 | 2003-09-08 | ||
| EP03103335 | 2003-09-10 | ||
| EP03103668 | 2003-10-02 | ||
| US50848603P | 2003-10-03 | 2003-10-03 | |
| EP04787096.9A EP1663240B2 (fr) | 2003-09-03 | 2004-09-03 | Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) |
| PCT/EP2004/052028 WO2005021001A1 (fr) | 2003-09-03 | 2004-09-03 | Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92854I2 true LU92854I2 (fr) | 2015-12-21 |
Family
ID=34280181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92853C LU92853I2 (fr) | 2003-09-03 | 2015-10-20 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine |
| LU92854C LU92854I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil |
| LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92853C LU92853I2 (fr) | 2003-09-03 | 2015-10-20 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US20080200435A1 (fr) |
| EP (1) | EP1663240B2 (fr) |
| JP (3) | JP5507791B2 (fr) |
| KR (1) | KR20060090658A (fr) |
| CN (1) | CN101060844B (fr) |
| AP (1) | AP2109A (fr) |
| AU (5) | AU2004268390B2 (fr) |
| BE (1) | BE2015C053I2 (fr) |
| CA (1) | CA2537095C (fr) |
| CY (5) | CY2015038I2 (fr) |
| FI (1) | FI1663240T4 (fr) |
| FR (3) | FR15C0073I2 (fr) |
| HK (1) | HK1092698A1 (fr) |
| HR (1) | HRP20150798T4 (fr) |
| HU (5) | HUS1500052I1 (fr) |
| IL (2) | IL173438A (fr) |
| LT (2) | LTC1663240I2 (fr) |
| LU (3) | LU92853I2 (fr) |
| MX (1) | MXPA06002437A (fr) |
| MY (1) | MY169670A (fr) |
| NL (2) | NL300781I2 (fr) |
| NO (6) | NO334877B1 (fr) |
| NZ (1) | NZ545306A (fr) |
| PL (1) | PL1663240T5 (fr) |
| WO (1) | WO2005021001A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| JP4822707B2 (ja) | 2002-08-09 | 2011-11-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法 |
| ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
| CN101068597B (zh) * | 2004-09-02 | 2012-04-18 | 詹森药业有限公司 | 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐 |
| PL1632232T6 (pl) * | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| EP1789139B1 (fr) * | 2004-09-02 | 2012-03-21 | Janssen Pharmaceutica NV | Hydrochloride de 4-((4-((4-(2-cyanoéthényl)-2,6-diméthylphényl amino -2-pyrimidinyl amino benzonitrile |
| EP1632232B3 (fr) * | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
| EA011036B1 (ru) * | 2004-09-02 | 2008-12-30 | Янссен Фармацевтика Н.В. | Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила |
| TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| SI2051703T1 (sl) * | 2005-12-14 | 2011-01-31 | Cipla Ltd | Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike |
| DK1981506T6 (da) * | 2006-01-20 | 2021-06-14 | Janssen Sciences Ireland Unlimited Co | Langtidsbehandling af hiv-infektion med tcm278 |
| US9044509B2 (en) * | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| JP5570999B2 (ja) | 2008-01-03 | 2014-08-13 | ユニベルシテ デ―マルセイユ | 抗ｈｉｖ治療の際に使用される組成物 |
| MY160360A (en) * | 2008-12-24 | 2017-02-28 | Janssen Sciences Ireland Uc | Implantable devices for treating hiv |
| CA2784530C (fr) | 2009-12-21 | 2018-05-22 | Janssen R&D Ireland | Implant s'eliminant par degradation pour la liberation prolongee d'un principe actif |
| KR20170078868A (ko) | 2010-01-27 | 2017-07-07 | 비이브 헬쓰케어 컴퍼니 | 항바이러스 치료 |
| ME01980B (fr) * | 2010-11-19 | 2015-05-20 | Gilead Sciences Inc | Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil |
| WO2012125993A1 (fr) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Formes à l'état solide de base rilpivirine et sels de rilpivirine |
| EP2755959B1 (fr) * | 2011-09-16 | 2018-05-16 | Hetero Research Foundation | Chlorhydrate de rilpivirine |
| ES2926068T3 (es) | 2012-12-21 | 2022-10-21 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico |
| SG11201802983TA (en) | 2015-11-09 | 2018-05-30 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
| ES2970870T3 (es) | 2016-10-24 | 2024-05-31 | Janssen Sciences Ireland Unlimited Co | Composiciones dispersables |
| WO2018119371A1 (fr) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Activité anti-flaviviridae d'inhibiteurs de la transcriptase inverse nucléosidiques et non nucléosidiques anti-rétroviraux (nnrtis) |
| US11234981B2 (en) | 2017-04-18 | 2022-02-01 | Cipla Limited | Combination therapy for use in treating retroviral infections |
| WO2019021319A1 (fr) * | 2017-07-27 | 2019-01-31 | Cipla Limited | Compositions pharmaceutiques |
| WO2021104487A1 (fr) | 2019-11-29 | 2021-06-03 | Aptorum Therapeutics Limited | Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182111A (en) * | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5368864A (en) * | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
| MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| KR0172134B1 (ko) | 1990-07-19 | 1999-02-01 | 오오쓰까 아끼히코 | 고형 제제 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JPH07503943A (ja) * | 1991-10-29 | 1995-04-27 | クローバー コンソリデイテッド，リミテッド | 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質 |
| EP0639971B1 (fr) | 1992-05-13 | 1999-09-22 | The Wellcome Foundation Limited | Combinaisons therapeutiques |
| JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
| TW401303B (en) | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
| IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| EP1214059B1 (fr) | 1999-09-21 | 2005-05-25 | Skyepharma Canada Inc. | Compositions particulaires, a surface modifiee, de substances biologiquement actives |
| US6743446B2 (en) * | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| TWI284048B (en) * | 2000-01-27 | 2007-07-21 | Zentaris Ag | Compressed microparticles for dry injection |
| GEP20043285B (en) | 2000-03-30 | 2004-07-26 | Bristol Myers Squibb Co | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections |
| US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| DE10050199A1 (de) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Flächiges Implantat mit im Ultraschall detektierbaren Elementen |
| CN1487935A (zh) | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 改良型水溶性药物组合物 |
| BR0210518A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de drogas e polìmeros neutros |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| CA2465779A1 (fr) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions destinees a la liberation de produits a action continue |
| JP4822707B2 (ja) | 2002-08-09 | 2011-11-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法 |
| WO2004022033A1 (fr) * | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Technique et dispositif d'apport commande d'hormone parathyroide |
| CA2505130C (fr) | 2002-11-08 | 2009-10-06 | Glaxo Group Limited | Compositions pharmaceutiques |
| AP1927A (en) | 2002-11-15 | 2008-12-10 | Tibotec Pharm Ltd | Substituted indolepyridinium as anti-infective compounds |
| AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| US20070021449A1 (en) | 2003-02-07 | 2007-01-25 | Jan Heeres | Pyrimidine derivatives for the prevention of hiv infection |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| BRPI0511900A (pt) | 2004-06-08 | 2008-01-22 | Vertex Pharma | composições farmacêuticas |
| MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| EP1632232B3 (fr) | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
| PL1632232T6 (pl) | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| KR20130030305A (ko) | 2004-11-16 | 2013-03-26 | 엘란 파마 인터내셔널 리미티드 | 주사가능한 나노입자형 올란자핀 제형 |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
| US20060269475A1 (en) * | 2005-04-11 | 2006-11-30 | Ryu Wonhyoung | Multi-layer structure having a predetermined layer pattern including an agent |
| US20090142401A1 (en) | 2005-06-07 | 2009-06-04 | Leah Elizabeth Appel | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
| WO2007014393A2 (fr) | 2005-07-28 | 2007-02-01 | Isp Investments Inc. | Efavirenz amorphe et methode de production |
| DK1981506T6 (da) | 2006-01-20 | 2021-06-14 | Janssen Sciences Ireland Unlimited Co | Langtidsbehandling af hiv-infektion med tcm278 |
| CL2007001847A1 (es) | 2006-06-23 | 2008-02-08 | Tibotec Pharm Ltd | Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih. |
| US20080081064A1 (en) * | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| EP2175857B1 (fr) | 2007-07-12 | 2013-09-11 | Janssen R&D Ireland | Forme cristalline de (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-diméthylphényl]amino]-2-pyrimidinyl]amino]benzonitrile |
| US20090123508A1 (en) | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
| WO2010047819A1 (fr) * | 2008-10-24 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Dérivés d'hydroxyéthylaminosulfonamide |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/fr not_active Expired - Lifetime
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 CA CA2537095A patent/CA2537095C/fr not_active Expired - Lifetime
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko active Search and Examination
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/fr active Application Filing
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/xx not_active IP Right Cessation
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/fr unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/el unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I2/el unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/fr unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/fr unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I1/el unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92854I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| WO2002042462A3 (fr) | Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique | |
| LU92496I2 (fr) | Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de merformineou d'un sel pharmaceutiquement acceptable de cell-ci, telle que protégée par le brevet de base EP1506211 B1 | |
| BR0308452A (pt) | composições farmacêuticas e métodos de preparação de composição farmacêutica | |
| GB0223040D0 (en) | Therapeutic compounds | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| UA90518C2 (ru) | Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| TNSN04165A1 (en) | Substituted hydroxyethylamines | |
| BR0209020A (pt) | Composição farmacêutica de polialilamina | |
| MXPA04000278A (es) | Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales. | |
| TNSN04071A1 (fr) | Derives de 3-azabicyclo [3.1.0] hexane servant d'antagonistes des recepteurs d'opioides | |
| SE0102440D0 (sv) | New compound | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| SG153661A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
| SG160197A1 (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | |
| PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors | |
| DE60137451D1 (de) | N-substituierte Amide als NK1 Rezeptor Antagonisten | |
| WO2005121074A3 (fr) | Procedes pour la preparation de chlorhydrate de sertraline | |
| MXPA01009032A (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12. | |
| NO20033634L (no) | GLyT-1-inhibitorer |